ACUTE-GO is a Study Testing the Effectiveness and Safety of Two Doses of Purified Cortrophin Gel in Patients With Acute Gouty Arthritis Flares (ACUTE-GO)
A Randomized, Multi-Center, Double-blind, Efficacy and Safety Study of Two Dose Levels of Purified Cortrophin® Gel in Patients With Acute Gouty Arthritis Flares
The goal of this clinical trial is to learn if Purified Cortrophin Gel can help people with acute gouty arthritis when they are having a sudden flare-up. It will also monitor participants for any potential side effects while on this therapy. The main question it aims to answer is: is there a change in gout pain intensity after receiving Purified Cortrophin Gel.
Researchers will compare two different doses of Purified Cortrophin Gel.
Participants will:
- Receive one injection of Purified Cortrophin Gel
- Have 2 in-person visits to the site and 3 virtual/telephone visits
- Complete daily surveys about their gout flare
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Ashley Gantt
- Número de telefone: 678-527-1332
- E-mail: ashley.gantt@anipharmaceuticals.com
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Recrutamento
- Mass General Hospital
-
Investigador principal:
- Hyon K Choi, MD, DrPH
-
Contato:
- Ana D Fernandes, MA
- Número de telefone: 617-643-2140
- E-mail: adfernandes@mgh.harvard.edu
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Main inclusion criteria:
-
Signed informed consent to participate in this study.
-
Male and female patients, aged 18-90 years.
-
Meeting the 2015 Gout classification criteria of the ACR/EULAR collaborative initiative.
-
Onset of current acute gout flare within 5 days prior to study entry
-
Baseline pain intensity ≥ 50 mm on the 0-100 mm visual analog scale (VAS).
-
History of ≥ 1 gout flares within the 12 months prior to study entry
-
The patient meets at least one of the following criteria for NSAIDs or colchicine treatment options:
- Minimum of one episode of inadequate response to treatment.
- The investigator deems that the patient is either contraindicated or inappropriate for treatment with NSAIDs or colchicine. Inappropriateness could be due to anticipated changes in patient status (i.e., such as worsening of comorbidities or use of concomitant medication).
-
Patients must be willing and capable of using, and have access to, an electronic device (e.g., cellphone or internet connected computer/tablet) to be able to complete surveys.
Main exclusion criteria:
-
Patients with active or known history of scleroderma, osteoporosis, active or recurrent bacterial, fungal or viral infections, or ocular herpes simplex.
-
Recent surgery (within 2 weeks prior to randomization or have an unhealed operation wound(s)).
-
Patients with active or known history of a peptic ulcer, uncontrolled congestive heart failure, uncontrolled hypertension, or uncontrolled diabetes type 1 or 2, as deemed by investigator.
-
Patients with sensitivity to proteins derived from porcine sources.
-
Patients with primary adrenocortical insufficiency or adrenocortical hyperfunction.
-
Active flare of rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at baseline.
-
Polyarticular gouty arthritis flare currently active in more than 4 joints.
-
Patients who have taken an investigational drug within five times the half-life of that investigational drug has passed or within 30 days of randomization.
-
Previous inclusion in this study.
-
Patients currently receiving dialysis.
-
Uncontrolled clinically significant hematologic, CNS, hepatic, pulmonary, gastrointestinal, metabolic, or endocrine disease as deemed by the investigator.
-
Presence of any medical or psychological condition or laboratory result that might create risk to the patients (or interfere with the patient's ability to comply with the protocol requirements, or to complete the study) in the opinion of the investigator.
-
Prior or current treatment with any ACTH product.
-
Pregnant or nursing (lactating) women. Women of childbearing potential are required to be using an acceptable method of contraception.
- Contraception must be used for the entire study and for at least 30 days after the last dose of study drug.
- Acceptable methods of contraception are:
i. hormonal methods, such as birth control pills, patches, injections, vaginal rings, or implants ii. barrier methods (such as a condom or diaphragm) used with a spermicide (a foam, cream, or gel that kills sperm) iii. intrauterine device (IUD) iv. abstinence (no sex)
-
Patients taking urate-lowering therapy have to be on a stable dose and regimen for ≥2 weeks before entering the study and remain on a stable dosage and regimen for at least 1 week after Purified Cortrophin® Gel.
-
Use of specified pain relief medications or biologics (including glucocorticoids, narcotics, paracetamol/acetaminophen, NSAIDs, colchicine, IL-blockers and tumor necrosis factor [TNF] inhibitors) within specified periods prior to randomization.
-
Vaccination within 30 days prior to study enrollment and during the study period.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: 40 U Purified Cortrophin Gel
|
One injection of Purified Cortrophin Gel, 40 U |
|
Comparador Ativo: 80 U Purified Cortrophin Gel
|
One injection of Purified Cortrophin Gel, 80 U |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in gout pain intensity from baseline in the target joint following PCG administration.
Prazo: From baseline to Day 3
|
Change in gout pain intensity from baseline in the target joint following PCG administration measured by Visual Analog Scale (VAS) at 72 hours post-injection (Day 3) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain. |
From baseline to Day 3
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured by Visual Analog Scale (VAS) at Day 1 (24 hours post-injection)
Prazo: Baseline to Day 1
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration measured at Day 1 (24 hours post-injection) on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 |
Baseline to Day 1
|
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured by Visual Analog Scale (VAS) at Day 2 (48 hours post-injection)
Prazo: Baseline to Day 2
|
Change in gout pain intensity from baseline in the target joint following Purified Cortrophin® Gel administration as measured on a 0-100 mm Visual Analog Scale (VAS), where 0 = no pain and 100 = unbearable pain; higher scores indicate worse (more severe) pain. |
Baseline to Day 2
|
|
Change in pain intensity timeline at baseline, 24 hours, 48 hours, 72 hours, and Day 7 post-injection
Prazo: Baseline to Day 7
|
Baseline to Day 7
|
|
|
Time to onset of effect (≥20% change from baseline pain intensity on VAS)
Prazo: Baseline to Day 7
|
Baseline to Day 7
|
|
|
Time to response (≥50% change from baseline pain intensity on VAS)
Prazo: Baseline to Day 7
|
Baseline to Day 7
|
|
|
Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale)
Prazo: Baseline to Day 7
|
Patient Global Self-Assessment of Response to Treatment (5-Point Likert Scale) 24 hours, 48 hours, 72 hours, and Day 7 post-injection scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response. |
Baseline to Day 7
|
|
Physician-Assessed Inflammatory Signs of the Index Joint (Joint Tenderness, Swelling, Range of Motion, and Erythema)
Prazo: Baseline to Day 3
|
Investigator-assessed composite of inflammatory signs in the index (most affected) joint, evaluated at baseline (Day 0) and 72 hours post-injection (Day 3): Joint tenderness - assessed via palpation/passive motion on a 4-point Likert scale: 0 (no pain) to 3 (severe/patient winces and withdraws); lower scores indicate better outcome. Joint swelling - 4-point Likert scale: 0 (no swelling) to 3 (severe swelling/bulging beyond joint margins); lower scores indicate better outcome. Target joint range of motion - 5-point Likert scale: 0 (normal) to 4 (immobilized); lower scores indicate better outcome. Erythema - categorical assessment: present, absent, or not assessable. |
Baseline to Day 3
|
|
Physician assessment of local tolerability at injection site (at 72 hours post-injection) - Number of Participants with Injection Site Reactions (Adverse Events)
Prazo: Baseline to Day 3
|
Local tolerability at the injection site will be assessed via investigator-reported adverse events. Injection site reactions occurring after study drug administration will be captured. The AE will be graded based on severity: MILD/MODERATE/SEVERE and causality: related/not related to study drug. |
Baseline to Day 3
|
|
Physician's Global Assessment of Response to Treatment (5-Point Likert Scale)
Prazo: Baseline to Day 3
|
Physician's Global Assessment of Response to Treatment (5-Point Likert Scale) scored 0 (Poor) to 4 (Excellent); higher scores indicate a better response. |
Baseline to Day 3
|
|
Use of rescue medication (up to 72-hours post-injection)
Prazo: Baseline to Day 3
|
Baseline to Day 3
|
|
|
Safety and Tolerability Assessments (Adverse Events, Serious Adverse Events, Clinical Laboratory Parameters, and Vital Signs)
Prazo: Baseline to Day 7
|
Safety will be assessed as follows: Adverse Events (AEs) and Serious Adverse Events (SAEs) - collected from study drug administration through Day 7, graded by the investigator as MILD, MODERATE, or SEVERE, and assessed for causality (related/not related to study drug). Clinical laboratory safety parameters - collected at baseline (Day 0) and Day 3, including biochemistry (AST, ALT, total bilirubin, ALP, PT/INR, albumin, total/LDL/HDL cholesterol, triglycerides, creatinine, sodium, potassium, ferritin, uric acid, glucose, HbA1c, troponin T, CRP, calcium, magnesium), hematology (hemoglobin, hematocrit, WBC with differential, platelets, ESR), and urinalysis (albumin, erythrocytes, hCG where applicable). Vital signs - systolic and diastolic blood pressure (mmHg), heart rate (bpm), and body temperature (°F), collected at baseline (Day 0) and Day 3, following a 5-minute rest period. |
Baseline to Day 7
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline in Serum C-Reactive Protein (CRP) Level
Prazo: Baseline to Day 3
|
Levels of C-reactive protein inflammatory markers (baseline [Day 0], 72 hours [Day 3]) continuous biomarker in mg/L (confirm units with your lab). Increasing CRP reflects worsening inflammation |
Baseline to Day 3
|
|
Change from Baseline in Gout Attack Intensity Score (GAIS)
Prazo: Baseline to Day 3
|
Change from baseline in health-related quality-of-life Gout Attack Intensity Score (GAIS) at Day 0 and at Day 3 (72-hours post-injection). GAIS is the mean of 3 patient-reported items (pain, tenderness, swelling), each scored 1-5; range 1-5, with higher scores indicating worse (more severe) gout attack intensity. |
Baseline to Day 3
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Artropatias Cristais
- Doenças musculoesqueléticas
- Artrite
- Doenças articulares
- Doenças Reumáticas
- Metabolismo de Purina-Pirimidina, Erros Inatos
- Metabolismo, Erros Inatos
- Doenças Genéticas, Congênitas
- Doenças Metabólicas
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças Nutricionais e Metabólicas
- Gota
Outros números de identificação do estudo
Outros números de identificação do estudo
- ANI-PCG-003
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .